Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Zimmer, Lisa; Livingstone, Elisabeth; Hassel, Jessica C.; Fluck, Michael; Eigentler, Thomas; Loquai, Carmen; Haferkamp, Sebastian; Gutzmer, Ralf; Meier, Friedegund; Mohr, Peter; Hauschild, Axel; Schilling, Bastian; Menzer, Christian; Kieker, Felix; Dippel, Edgar; Roesch, Alexander; Simon, Jan-Christoph; Conrad, Beate; Koerner, Silvia; Windemuth-Kieselbach, Christine; Schwarz, Leonora; Garbe, Claus; Becker, Juergen C.; Schadendorf, Dirk

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Autor(en):

Zimmer, Lisa; Livingstone, Elisabeth; Hassel, Jessica C.; Fluck, Michael; Eigentler, Thomas; Loquai, Carmen; Haferkamp, Sebastian; Gutzmer, Ralf; Meier, Friedegund; Mohr, Peter; Hauschild, Axel; Schilling, Bastian; Menzer, Christian; Kieker, Felix; Dippel, Edgar; Roesch, Alexander; Simon, Jan-Christoph; Conrad, Beate; Koerner, Silvia; Windemuth-Kieselbach, Christine; Schwarz, Leonora; Garbe, Claus; Becker, Juergen C.; Schadendorf, Dirk

Tübinger Autor(en):

Eigentler, Thomas
Garbe, Claus

Erschienen in:

Lancet (2020), Bd. 395, H. 10236, S. 1558-1568

Verlagsangabe:

Elsevier Science Inc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/S0140-6736(20)30417-7

ISSN:

1474-547X